Pre-market Hot Trades in US Stocks

Jaguar Health is up 5.62% in pre-market trading. Based on recent news,

1. On July 14, Jaguar Health announced through the EDGAR system that it had signed a new manufacturing and supply agreement with Napo and Alivus. This agreement includes a minimum purchase commitment from Napo for Crofelemer and will expire on March 31, 2029. This news boosted market confidence and drove the stock price up.

2. On July 14, Jaguar Health disclosed the details of the above agreement in an SEC filing, further confirming the validity of the agreement and the prospects for long-term cooperation, enhancing investor confidence.

3. On July 14, the 8-K filing released by Jaguar Health detailed the terms and conditions of the new agreement, ensuring optimistic market expectations for the company's future performance, leading to an increase in stock price. The market reacted positively to the new agreement, driving the stock price up.

Arm is down 3.24% in pre-market trading. Based on recent news,

1. On July 17, HSBC downgraded Arm Holdings from "Buy" to "Hold," believing that its server CPU growth expectations are overly optimistic and that the valuation is high, leading to a decline in stock price. HSBC pointed out that Arm's strong growth has significantly factored in its long-term AI growth potential into its valuation, leaving limited upside.

2. On July 15, HSBC analyst Frank Lee stated that Arm's stock price has fully reflected strong long-term growth expectations, and short-term profit upside is constrained by TSMC's insufficient 3nm wafer capacity, putting pressure on the stock price.

3. On July 14, Arteris announced an expansion of its collaboration with Arm Holdings to enhance the security of processor core development. Although this news provided some support for the stock price, overall market concerns about AI investment returns continued to weigh on stock performance. The AI and semiconductor industries have recently shown divergent performance, necessitating attention to valuation risks.

Top Gainers in Pre-market US Stocks

Polestar is up 319.11% in pre-market trading. Based on recent key news:

1. On July 16, Lucid Motors faced bankruptcy rumors, which the company denied, but it impacted confidence in the electric vehicle industry, leading to volatility in Polestar's stock price. Investors have doubts about the long-term viability of electric vehicle companies, affecting Polestar's market performance.

2. On July 17, the Chief Financial Officer of Volvo Cars stated that there are currently no plans to inject capital into Polestar. This news may affect market expectations regarding Polestar's future liquidity, thereby impacting the stock price.

3. On July 17, the CEO of Volvo Cars confirmed that it holds a 20% stake in Polestar and has no intention of changing its shareholding ratio. This statement stabilized market expectations regarding Polestar's equity structure, reducing uncertainty. The electric vehicle industry faces risks from policy changes and demand slowdown Sadot pre-market up 47.02%. Based on recent key news:

4. On July 16, Sadot Group Inc. announced through the EDGAR system the termination of its $10 million equity credit facility agreement with Helena Global Investment Opportunities I. This move aims to resolve litigation and end financing obligations, with the agreement termination date set for July 15, involving an exit fee of $350,000. Following this announcement, market expectations for Sadot's financial condition improved, driving a significant increase in its stock price. The U.S. stock market has seen increased volatility recently, and investors should exercise caution.

Callan JMB pre-market up 45.18%. Based on recent news,

1. On July 16, the management team projected that the project would generate approximately $414 million in revenue for Callan JMB over the next five years and believes this will help create a cutting-edge pharmaceutical manufacturing environment in the U.S. This news boosted market confidence, driving the stock price up.

2. On July 17, Benzinga Pro data showed that Callan JMB's closing price during regular trading hours on Thursday was $0.86, up 16.51%. Nevertheless, Benzinga's Edge stock ranking indicates that CJMB stock's price trend is negative across all time frames.

3. On July 17, GrowHub announced a $400 million merger agreement with EnChem, with its stock price soaring over 86%. Although this is not directly related to Callan JMB, it demonstrates the market's positive reaction to significant merger news, indirectly affecting investor sentiment. The market reacted positively to major merger news, and investor sentiment is high